Don't Hold Your Breath Waiting for a VIVUS Inc. Buyout

Last week, Aspen Investment disclosed a 9.65% stake in VIVUS (NASDAQ: VVUS  ) and said it's considering a $640 million purchase, which would be made definitive by June 13.

As senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss in the following video, the key word there is "considering." By the size of its investment, it's clear Aspen thinks VIVUS is undervalued, but it's not clear whether the potential bid is a serious one or just a ploy to try to get the shares higher.

If it is a serious bid, it might not be the best news for Arena Pharmaceuticals (NASDAQ: ARNA  ) and Orexigen (NASDAQ: OREX  ) , as it would put a floor on the potential price for obesity drugmakers. Arena Pharmaceuticals and Orexigen would be better off if VIVUS was being pursued by a large pharma, as it would give investors confidence that Arena and Orexigen might eventually be taken out by their respective partners, Eisai and Takeda.

Obesity drugmakers might be struggling, but our CIO likes this stock
Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! You don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Read/Post Comments (7) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 05, 2014, at 8:57 PM, IraHopp wrote:

    Like Sara Pella use to say wheres the beef.Article has nothing to do with headline.Seeing vvus has 200 million in cash that would lower the take over for Aspen from 620 a share to about 420 a share. It never get mentioned

  • Report this Comment On June 06, 2014, at 4:05 AM, marp11 wrote:

    poor osmelli

    confusing a 2 generic loser again

    with a real bio pharma..

    osmelli makes AF look good.

  • Report this Comment On June 06, 2014, at 4:07 AM, marp11 wrote:

    what osmelli means is if a craphole like vvus

    got 640 million

    a real company like ARNA with cash,partners,pipeline and LOCASERIN

    would fetch over 10 BILLION

    and that terrifies brian and his ARNA SHORT MASTERS

  • Report this Comment On June 06, 2014, at 7:51 AM, OriginalNewman1 wrote:

    Now that OREX has passed the FDA scrutiny

    on the results of the Phase 3 tests, and apparently it also looks like the Light Study (8900 Patients) which was over and above the required amount)on heart related issues showed no dangers for any cardiac concerns.

    How else will the FDA find a way to delay CONTRAVE????? esp. when they Didn't require the other two companies from conducting any of these tests.

  • Report this Comment On June 07, 2014, at 12:58 AM, Vanmusicblues wrote:

    The floor comes from turning losses into profits. VVUS is now valued on Stendra, not Q

  • Report this Comment On June 07, 2014, at 9:33 AM, MichaelHamilton wrote:

    There is no reason why this company should be valued less than Arena. It has higher sales and more products. Whoever buys this company at $640m will get a bargain price though I don't think a large pharma would be interested.

  • Report this Comment On June 09, 2014, at 3:42 PM, gazoo99 wrote:

    VVUS is a Joke & Broke.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2983148, ~/Articles/ArticleHandler.aspx, 9/1/2015 12:19:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated Moments ago Sponsored by:
DOW 16,174.57 -353.46 -2.14%
S&P 500 1,930.29 -41.89 -2.12%
NASD 4,694.41 -82.10 -1.72%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 12:03 PM
VVUS $1.18 Up +0.05 +4.42%
VIVUS, Inc. CAPS Rating: **
ARNA $2.63 Down -0.08 -2.95%
Arena Pharmaceutic… CAPS Rating: **
OREX $2.71 Down -0.06 -2.17%
Orexigen Therapeut… CAPS Rating: **